logo
ResearchBunny Logo
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Medicine and Health

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

M. E. Layton, J. C. Kern, et al.

Discover how the inhibition of Phosphodiesterase 10A (PDE10A) could revolutionize schizophrenia treatment by normalizing striatal activity. This exciting research conducted by Mark E Layton and colleagues unveils MK-8189, a powerful PDE10A inhibitor currently undergoing Phase 2b clinical development.

00:00
00:00
Playback language: English
Abstract
Phosphodiesterase 10A (PDE10A) inhibition offers a novel mechanism for treating schizophrenia by normalizing dysfunctional striatal activity. This paper details the discovery of MK-8189 (compound 18), a highly potent and selective PDE10A inhibitor, stemming from the optimization of a fragment hit. The optimization addressed liabilities such as poor pharmacokinetic properties, off-target activities, and low solubility, resulting in a compound currently in Phase 2b clinical development for schizophrenia.
Publisher
Journal of Medicinal Chemistry
Published On
Jan 01, 2023
Authors
Mark E Layton, Jeffrey C Kern, Timothy J Hartingh, William D Shipe, Izzat Raheem, Monika Kandebo, Robert P Hayes, Sarah Huszar, Donnie Eddins, Bennett Ma, Joy Fuerst, Gordon K Wollenberg, Jing Li, Jeff Fritzen, Georgia B Mcgaughey, Jason M Uslaner, Sean M Smith, Paul J Coleman, Christopher D Cox
Tags
PDE10A
schizophrenia
MK-8189
inhibition
clinical development
potent inhibitor
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny